Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 438-442

  Trask, Peter C ^a,b   Cella, David ^c   Besson, Nadine ^d   Kelly, Virginia ^a   Masszi, Tamás ^e   Kim, Dong Wook ^f  

^a PFIZER INC   (United States)

^b Sanofi Aventis   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e Szent Laszlo Hospital   (Hungary)

^f The Catholic University of Korea   (South Korea)

Author keywords

Bosutinib; Chronic myeloid leukemia; Chronic phase; FACT Leu; Health related quality of life

Indexed keywords

BOSUTINIB; IMATINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETERIORATION; DRUG DOSE ESCALATION; EMOTIONAL WELL BEING; FAMILY WELL BEING; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; FUNCTIONAL ASSESSMENT OF CANCER THERAPY LEUKEMIA; FUNCTIONAL ASSESSMENT OF CANCER THERAPY TRIAL OUTCOME INDEX; HUMAN; IMATINIB INTOLERANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; IMATINIB RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PHYSICAL WELL BEING; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SOCIAL WELL BEING; TREATMENT DURATION; WELLBEING;

EID: 84857234074     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.10.011     Document Type: Article

References (16)

1. American Cancer Society Cancer facts and figures 2010 2010, American Cancer Society, Atlanta.
2. Baccarani M., Dreyling M. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v165-v167.
3. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11):994-1004.
4. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23):2408-2417.
5. Hochhaus A., O'Brien S.G., Guilhot F., Druker B.J., Branford S., Foroni L., et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
6. Efficace F., Kemmler G., Vignetti M., Mandelli F., Molica S., Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer 2008, 44(11):1497-1506.
7. Efficace F., Cocks K., Breccia M., Sprangers M., Meyers C.A., Vignetti M., et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2011, [epub ahead of print].
8. Hahn E.A., Glendenning G.A., Sorensen M.V., et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003, 21:2138-2146.
9. Brucker P.S., Yost K., Cashy J., Webster K., Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005, 28:192-211.
10. Cella D, Webster K, Beaumont J, Du H, Lai J-S, Rosen S, Tallman M, Yount S. Measuring health-related quality of life in leukemia: the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire, submitted for publication.
11. Cella D. The manual of the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Center on outcomes, research and education 1997, Evanston Northwestern Healthcare and Northwestern University.
12. Cella D.F., Tulsky D.S., Gray G., et al. The Functional Assessment of Cancer Therapy (FACT) scale: development and validation of the general measure. J Clin Oncol 1993, 11(3):570-579.
13. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(24):2531-2541.
14. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
15. Kantarjian H.M., Giles F.J., Bhalla K.N., Pinilla-Ibarz J., Larson R.A., Gattermann N., et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117(4):1141-1145.
16. Brümmendorf T.H., Cortes J.E., Turkina A., et al. Safety and efficacy of second-line bosutinib (SKI-606) in imatinib-resistant or -intolerant chronic phase (CP) chronic myeloid leukemia (CML). Paper Presented at: 15th Congress of the European Hematology Association 2010.